Findings

What do systematic reviews say?

Refine by population, intervention, comparison or outcome
More filters
Evidence found and GRADE certainty

1,062 questions · 1,113 findings · 171 reviews · Headline outcomes only

No studies found 161 · 14.5%GRADE not reported 41 · 3.7%Very low 269 · 24.2%Low 321 · 28.8%Moderate 252 · 22.6%High 69 · 6.2%

Alemtuzumab 12 mg vs interferon beta‐1a

Number of participants with new T2‐hyperintense lesions on magnetic resonance imaging · patients with relapsing‐remitting multiple sclerosis

Alemtuzumab 12 mg may leads to lower number of participants with new T2‐hyperintense lesions on magnetic… compared with interferon beta 1a (low certainty).

1 finding from 1 review

Alemtuzumab 12 mg vs interferon beta‐1a

Number of participants with adverse events leading to study discontinuation · patients with relapsing‐remitting multiple sclerosis

Alemtuzumab 12 mg may leads to lower number of participants experiencing treatment discontinuation caused… compared with interferon beta 1a (low certainty).

1 finding from 1 review

Intervention not reported

Very preterm birth (less than 34 weeks) ‐ assuming complete correlation between twins/triplets · women with multiple pregnancy

The intervention showed no clear difference in very preterm birth (less than 34 weeks) ‐ assuming complete… (low certainty).

1 finding from 1 review

Intervention not reported

Low birthweight (less than 2500 g) ‐ assuming independence between twins/triplets · women with multiple pregnancy

The intervention showed no clear difference in low birthweight (less than 2500 g) ‐ assuming independence between… (low certainty).

1 finding from 1 review

Intervention not reported

Very preterm birth (less than 34 weeks) ‐ assuming complete correlation between twins · women with multiple pregnancy

The intervention showed no clear difference in very preterm birth (less than 34 weeks) ‐ assuming complete… (low certainty).

1 finding from 1 review

Interferon vs glatiramer acetate

Number of participants with confirmed progression Risk ratio (M‐H, random, 95% CI) · patients with relapsing‐remitting multiple sclerosis

Interferons showed no clear difference in number of participants with confirmed progression Risk ratio (M‐H,… compared with glatiramer acetate (moderate certainty).

1 finding from 1 review